ideasIdea

Hospital-funded protected time for clinician-scientists, repaid by trial revenue

Doctors who could turn discoveries into trials are buried in clinical work. Hospitals would guarantee them research time and recover the cost from the trials and grants they bring in.

Cancer hospitals create a protected-time scheme (for example 40% for five years) for clinician-scientists leading translational projects, funded from a revolving pool seeded by philanthropy and repaid from the indirect costs of grants and per-patient trial income those clinicians generate. Selection is by translational plan and mentorship, not by publication record. Clinician-scientists are the people who take a lab finding into a phase 1 protocol, yet their numbers are falling in most countries because clinical productivity pays and research time is the first thing cut.

Hypothesis

Clinicians with guaranteed protected time initiate at least twice as many investigator-led trials and translational grants per head as matched colleagues without protected time, and the scheme becomes cost-neutral to the hospital within five years through recovered indirect costs and trial income.

Rationale

NIH's physician-scientist workforce report documents the decline; where protected time has been funded (Howard Hughes, Burroughs Wellcome career awards, UK academic clinical lecturer posts) retention and output are markedly higher. Trial income is a real revenue line at cancer centres and can be earmarked.

What would test it

Two cancer centres run the scheme for five years with financial tracking and compare trial initiations and grant income of protected clinicians with a matched internal control group.

Maturity

speculative

Who has to act

clinic

Cost to try

Medium ($1M to $50M)

Years to first evidence

Bottlenecks it attacks

The valley of death between lab and product · Most academic discoveries die before anyone tests them in people because nobody funds the middle step.
Not enough oncologists, nurses, pathologists, physicists · The number of people with cancer is rising faster than the workforce trained to treat them.

Connected

4top

Pages like this

not linked directly; found by shared links

ideas

Funded research pathways for surgeon-scientists and radiation oncologist-scientists Two-year translational fellowships that pay scientists to develop their own discovery

bottlenecks

Not enough oncologists, nurses, pathologists, physicists The valley of death between lab and product